Clinicopathologic features of kinase fusion-related thyroid carcinomas: an integrative analysis with molecular characterization
- 30 July 2020
- journal article
- research article
- Published by Elsevier BV in Laboratory Investigation
- Vol. 33 (12), 2458-2472
- https://doi.org/10.1038/s41379-020-0638-5
Abstract
No abstract availableFunding Information
- U.S. Department of Health & Human Services | NIH | National Cancer Institute (1P01CA240239-01, 1P01CA240239-01, 1P01CA240239-01)
- U.S. Department of Health & Human Services | NIH | National Cancer Institute
- U.S. Department of Health & Human Services | NIH | National Cancer Institute
This publication has 71 references indexed in Scilit:
- Identification of a Recurrent STRN/ALK Fusion in Thyroid CarcinomasPLOS ONE, 2014
- Identification of kinase fusion oncogenes in post-Chernobyl radiation-induced thyroid cancersJCI Insight, 2013
- Recurrent BRAF kinase fusions in melanocytic tumors offer an opportunity for targeted therapyPigment Cell & Melanoma Research, 2013
- A Novel ALK Secondary Mutation and EGFR Signaling Cause Resistance to ALK Kinase InhibitorsCancer Research, 2011
- Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicineEMBO Molecular Medicine, 2010
- Fast and accurate short read alignment with Burrows–Wheeler transformBioinformatics, 2009
- Diffuse sclerosing variant of papillary thyroid carcinoma: lack of BRAF mutation but occurrence of RET/PTC rearrangementsLaboratory Investigation, 2007
- Prognostic significance of RET and NTRK1 rearrangements in sporadic papillary thyroid carcinomaSurgery, 2000
- The ETV6-NTRK3 gene fusion encodes a chimeric protein tyrosine kinase that transforms NIH3T3 cellsOncogene, 2000
- The ret/PTC1 Rearrangement is a Common Feature of Chernobyl-Associated Papillary Thyroid Carcinomas from BelarusThyroid®, 1998